ad image

Company Info

Hovione

Hovione

CDMO / Excipients / Intermediates

Overview

Hovione is an international company with over 60 years of experience as a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substance, drug product intermediate and drug product. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solution across the entire drug life cycle. A leading provider of commercial spray drying services, Hovione has over 18 years of experience in particle engineering and is the leader in commercial spray drying services. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices. Hovione´s culture is based on innovation, quality, and delivery. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.
Hovione
Contributions
28 Contributions1 / 2
Hovione
Strategic Partnership

Hovione and Laxxon Medical Establish an Agreement for the cGMP Production of 3D Screen Printed Pharmaceutical Applications

Hovione

PR-M03-23-06Mar 22, 2023
Hovione
CDMO Leadership Award

Hovione Receives the 2023 CDMO Leadership Award in All Six Categories and Is Champion in Compatibility and Expertise

Hovione

PR-M03-23-01Mar 08, 2023
Hovione
Continuous Tableting

Hovione and GEA Announce a Strategic Collaboration to Advance Continuous Tableting

Hovione

PR-M12-22-02-176Dec 14, 2022
Hovione
Global License Agreement

Hovione and JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program

Hovione

PR-M05-22-04May 09, 2022
Hovione
Business Leadership

Jean-Luc Herbeaux to Become Hovione CEO

Hovione

PR-M02-22-23Feb 25, 2022
Hovione
Strategic Partnership

Hovione and Zerion Pharma Announce a Strategic Partnership to Market the Dispersome® Technology Platform

Hovione

PR-M02-22-19Feb 22, 2022
Hovione
Strategic Collaboration

Hovione and iBET Announce Strategic Collaboration

Hovione

PR-M05-21-020May 27, 2021
Hovione
Ophthalmology

Hovione Completes its Phase II Clinical Trial of the First Minocycline Ophthalmic Showing Promise in Dry Eye Disease Associated with Inflamed Meibomian Gland Dysfunction

Hovione

PR-M03-21-003Mar 17, 2021
Hovione
Screening Service

Hovione Launches ASD-HIPROS the Most Advanced Screening Service for Optimal Spray Dried Dispersions Formulation

Hovione

PR-M11-20-033Jan 12, 2021
Hovione
COVID-19

Hovione Announces Partnership to Support Manufacturing of Antiviral Veklury for COVID-19

Hovione

PR-M09-20-26Sep 23, 2020
Hovione
Leadership

Hovione Announces the Appointment of Jean-Luc Herbeaux as Chief Operating Officer

Hovione

PR-M05-20-NI-006May 04, 2020
Hovione
Phase II

Hovione Announces Successful End-of-Phase 2 Meeting with the FDA and Outlines Phase 3 Program for Minocycline Topical Gel

Hovione

PR-M09-19-NI-047Sep 20, 2019
Developing and Characterizing DPI Formulations for Biologics
Formulation

Developing and Characterizing DPI Formulations for Biologics

Eunice Costa; Constança Cacela

Hovione

PAP-Q1-2019-CL-002Apr 12, 2019
Hovione
Finance

Hovione Issues $50 Million Bond

Hovione

PR-M01-19-NI-081Jan 28, 2019
The Coming of Age of Amorphous Solid Dispersions
Formulation

The Coming of Age of Amorphous Solid Dispersions

Márcio Temtem, Ph.D.

Hovione

PAP-Q4-18-CL-004Oct 26, 2018
Hovione
Expanded Capacity

Hovione Reports on Recent Capacity Expansion and Future Plans to Support Growth

Hovione

PR-M03-18-NI-081Mar 22, 2018
Hovione
Regulatory

Compliance at Hovione, Annual Inspection Review

Hovione

PR-M03-18-NI-037Mar 12, 2018
Hovione
Inhalation

Hovione strengthens Inhalation Services portfolio

Hovione

PR-M01-18-NI-084Jan 24, 2018
Hovione
Clinical Trial

Hovione Announces Enrollment of First Patient in MARS a Phase 2 Clinical Trial 

Hovione

PR-M12-17-NI-005Dec 13, 2017
Speeding Development and Reducing Costs with Analytical Quality by Design
Quality by Design

Speeding Development and Reducing Costs with Analytical Quality by Design

António Ramos; Rui Loureiro

Hovione

PAP-Q2-17-CL-006Jun 05, 2017
1 / 2